Stockscreener 앱 받기
9.74
3.75%
-0.38
시간 외 거래:
9.91
0.17
+1.75%
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Monte Rosa Therapeutics (NasdaqGS:GLUE) Stock Forecast & Analyst Predictions - Simply Wall Street
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6%What's Next? - MarketBeat
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial - Kalkine Media
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com
Monte Rosa Therapeutics (Nasdaq:GLUE)Stock Analysis - Simply Wall Street
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE - MarketBeat
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Share Price, GLUE Stock News, GLUE Share Price & Updates - Kalkine
Can Monte Rosa Therapeutics (NASDAQ:GLUE) Rewrite Its Story? - Kalkine Media
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone - Yahoo Finance
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com India
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - moomoo.com
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
GLUE stock gains on investor conference plans and Monte Rosa outlook - ad-hoc-news.de
Six new hires get stock awards from Monte Rosa - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive - Sahm
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
7.64%
자본화:
|
볼륨(24시간):